… Vedolizumab is the first licensed drug in a group of ‘gut-selective’ biological agents used to
treat inflammatory bowel diseases… established the efficacy of vedolizumab for the induction …

… Many biologic therapies are being evaluated for the treatment of the chronic inflammatory
bowel diseases, Crohn's disease and ulcerative colitis. Biologic compounds proven to be …

… cells play pivotal roles in the pathogenesis of inflammatory bowel disease (IBD) ( 1 , 2 ). …
from the systemic circulation to inflamed tissues ( 3 , 4 , 5 , 6 ). Vedolizumab, a novel humanized …

… a bridge to maintenance vedolizumab treatment when applied to vedolizumab initiation or
… nonresponse to vedolizumab. On long-term follow-up evaluation, vedolizumab was able to …

… Crohn's disease and ulcerative colitis are chronic disabling inflammatory bowel diseases
(IBDs). Although the causes of IBD are unknown, defects in innate and adaptive immune …

… in managing ulcerative colitis (UC) and Crohn's disease (CD) patients with vedolizumab (VDZ)
are … in inflammatory bowel diseases (IBD) outpatients in primary gastroenterology centers. …

… Vedolizumab (VDZ) is a monoclonal antibody which blocks … remission in both ulcerative colitis
(UC) and Crohn's disease (CD). … in treating patients with inflammatory bowel disease (IBD) …

… Real-life data on vedolizumab effectiveness in inflammatory bowel disease (IBD) are still
emerging. Data on the comparative safety of the gut selective profile are of particular interest. …

… , vedolizumab is an effective treatment for moderate to severe CD and UC, offering an attractive
alternative to anti-TNFα therapy… surgery will be receiving vedolizumab therapy. We found …

… Nevertheless, important questions remain about the long-term safety (LTS) of vedolizumab
in patients with inflammatory bowel disease (IBD). To address this issue, the cumulative LTS …